Genetics of Pancreatic Cancer and Its Implications on Therapy.

Surg Clin North Am 2016 Dec;96(6):1207-1221

Department of Surgery, The Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut Street, Suite 605, Philadelphia, PA 19107, USA. Electronic address:

Over the past decade, emerging technologies have provided new insights into the genomic landscape of pancreatic ductal adenocarcinoma (PDA). In addition to the commonly recognized genetic drivers of pancreatic carcinogenesis (KRAS, CDKN2A, TP53, SMAD4), new genes and pathways have been implicated. However, these efforts have not identified any new high-frequency actionable mutations, limiting the success of mutation-targeted therapy in PDA. This article provides a report on the current landscape of pancreas cancer genetics and targeted therapeutics.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suc.2016.07.014DOI Listing
December 2016
9 Reads

Publication Analysis

Top Keywords

genes pathways
4
smad4 genes
4
pathways implicated
4
implicated efforts
4
identified high-frequency
4
efforts identified
4
tp53 smad4
4
cdkn2a tp53
4
recognized genetic
4
commonly recognized
4
genetic drivers
4
drivers pancreatic
4
kras cdkn2a
4
pancreatic carcinogenesis
4
high-frequency actionable
4
actionable mutations
4
landscape pancreas
4
current landscape
4
pancreas cancer
4
cancer genetics
4

Similar Publications